DR. マーク・シーゲル: “And there’s a lot of confusion, しかし、私があなたに伝えたいことが一つあります, 少なくともFDAは今回彼らの諮問グループを持ち込みました. 彼らは5歳から11歳のグループではそれをしないかもしれません. Why do I like that so much? I talked to Paul Offit, who’s a senior member of that committee, and he’s one of the top vaccinologists in the country. I talked to him yesterday. 彼は言った, ええと, it’s very clear that there’s a benefit over the age of 60. 私は言った, why 65? 彼は言った, 上手, it could have been 60. So over the age of 60, you’re seeing some benefit. And there’s 22 million Americans who have been more than six months out, and half of them are over the age of 65, ところで, they’re going to qualify if they got the Pfizer-BioNTech shot.
Now here’s where the confusion comes from, 痕跡. What does it mean that you need a booster? What does it actually mean? Because what they’re actually measuring is risks of mild infections, and does your antibody level go down? しかし、あなたは何を知っています? You have a memory of having had that vaccine and that ramps up when you see the virus. So that protects you against severe illness and hospitalization. So there’s no reason to think the vaccine doesn’t work beyond six months. It’s just not quite as effective. And we want to prevent spread. That’s the other thing. So you give a booster, you decrease your risk of spread, you decrease your risk of severe illness. We don’t know how long that lasts. The Israel data is only a few weeks out. We don’t know if that boost we give you is going to last and endure. The vaccine itself will endure. But again, it can diminish over time.”
WATCH THE FULL INTERVIEW HERE:
FOX Business’ Bradford Betz contributed to this report.